Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 9,830,000 shares, an increase of 28.2% from the October 15th total of 7,670,000 shares. Currently, 10.3% of the shares of the company are short sold. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is currently 4.9 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 10th. LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday. Finally, Scotiabank restated a “sector perform” rating and set a $1.00 price objective (down from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th.

Bionano Genomics Stock Down 3.8 %

BNGO opened at $0.25 on Friday. The stock has a fifty day moving average of $0.36 and a 200-day moving average of $0.60. The company has a market capitalization of $21.16 million, a P/E ratio of -0.05 and a beta of 2.37. Bionano Genomics has a fifty-two week low of $0.24 and a fifty-two week high of $2.27. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.11 and a current ratio of 1.63.

Institutional Trading of Bionano Genomics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Bionano Genomics during the first quarter worth approximately $36,000. Price T Rowe Associates Inc. MD lifted its position in shares of Bionano Genomics by 123.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after acquiring an additional 38,900 shares during the period. Armistice Capital LLC acquired a new stake in shares of Bionano Genomics during the 2nd quarter worth $1,138,000. Cetera Advisors LLC bought a new position in shares of Bionano Genomics in the first quarter worth $163,000. Finally, Carret Asset Management LLC raised its stake in Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after purchasing an additional 40,055 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.